SC
RARE icon

Steph & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Steph & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,386
Closed -$86.4K – 312
2025
Q1 		$86.4K Sell
2,386
-231
-9% -$9.61K 0.03% 156
2024
Q4 		$110K Sell
2,617
-180
-6% -$8.93K 0.04% 147
2024
Q3 		$155K Buy
+2,797
New +$142K 0.05% 137

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Steph & Co's RARE Position: Q2 2025 in Review

Steph & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 2,386 shares — an estimated $86.4K sold.

Steph & Co first reported a position in RARE in Q3 2024 and held it in 3 quarters. The position peaked at $155K in Q3 2024. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • Steph & Co reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Steph & Co sold 2,386 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $86.4K.
  • Steph & Co first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 3 quarters.
  • Steph & Co's Ultragenyx Pharmaceutical position peaked at $155K in Q3 2024.
  • 309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Steph & Co's 13F filing for Q2 2025, filed 16 Jul 2025.